Feb 26, 2026 04:05PM
Nov 18, 2025 08:01AM
Nov 18, 2025 08:00AM
Oct 29, 2025 04:15PM
Aug 6, 2025 04:15PM
May 7, 2025 04:05PM
Mar 3, 2025 04:23PM Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results
Dec 30, 2024 06:33AM
Dec 16, 2024 08:00AM
Dec 16, 2024 08:00AM
Nov 6, 2024 04:05PM
Sep 3, 2024 07:09AM
Sep 3, 2024 07:08AM
Sep 3, 2024 07:08AM Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile
Aug 6, 2024 05:01PM
Jul 31, 2024 08:53AM
May 1, 2024 04:57PM
Mar 6, 2024 04:31PM
Mar 6, 2024 04:31PM
Feb 21, 2024 07:03AM
Feb 21, 2024 07:00AM Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
Nov 28, 2023 06:59AM
Nov 8, 2023 05:38PM
Aug 8, 2023 04:31PM
May 15, 2023 07:36AM
May 9, 2023 04:05PM
Mar 29, 2023 01:58PM
Feb 27, 2023 04:42PM Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022
Feb 27, 2023 04:42PM
Feb 15, 2023 06:00AM
Feb 15, 2023 02:00AM
Feb 15, 2023 02:00AM
Feb 15, 2023 02:00AM
Jan 9, 2023 06:59AM
Jan 9, 2023 06:59AM Emergent BioSolutions Announces Organizational Changes as Part of Sharpened Strategic Focus
Jan 9, 2023 06:59AM
Nov 14, 2022 06:31AM
Nov 14, 2022 06:30AM
Nov 14, 2022 06:30AM
Nov 8, 2022 04:16PM
Nov 8, 2022 04:16PM
Sep 26, 2022 04:12PM Emergent BioSolutions Completes Acquisition of Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages
Sep 26, 2022 04:12PM
Aug 1, 2022 04:05PM
Aug 1, 2022 04:05PM
May 16, 2022 09:25AM
May 16, 2022 06:33AM
May 16, 2022 06:32AM
May 16, 2022 06:32AM Emergent BioSolutions to Acquire from Chimerix its Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages
Apr 28, 2022 04:05PM

1,122,779 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All